Based on the Uipath Inc stock forecast from 15 analysts, the average analyst target price for Uipath Inc is USD 15.42 over the next 12 months. Uipath Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Uipath Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Uipath Inc’s stock price was USD 12.37. Uipath Inc’s stock price has changed by -6.07% over the past week, -3.89% over the past month and -33.74% over the last year.
No recent analyst target price found for Uipath Inc
No recent average analyst rating found for Uipath Inc
Company Overview Uipath Inc
UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform's embedded AI, ML, and NLP capabilities improve decisioning and information processing; emulate human behavior allows organizations to address a myriad of use cases; emulate human behavior allows organizations to address a myriad of use cases; multi-tenant platform enterprise deployment with security and governance and Automation Cloud, which enables customers to begin automating without the need to provision infrastructure, install applications, or perform additional configurations; intuitive interface and low-code, drag-and-drop functionality; signed to enable people and automations to work together; and tracks, measures, and forecasts the performance of automations, enables customers to gain powerful insights and generate key performance indicators with actionable metric. It serves banking and financial services, healthcare, insurance, public sectors, manufacturing, retail, and telecom industries. The company was founded in 2005 and is headquartered in New York, New York. Read Less
UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build...Read More
Frequently Asked Questions About Uipath Inc (PATH) Stock
Based on ratings from 15 analysts Uipath Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 30 hold ratings.
Unfortunately we do not have enough data on PATH's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for PATH is USD 15.42 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 12.
PATH stock's Price/Earning ratio is 39.25.
Our analysis grades PATH stock's Price / Earning ratio at D. This means that PATH stock's Price/Earning ratio is above 35% of the stocks in the Software - Infrastructure sector in the NYE exchange.
Based on this PATH may be fairly valued for its sector
The last closing price of PATH's stock was USD 12.37.
The most recent market capitalization for PATH is USD 6.93B.
Based on targets from 15 analysts, the average taret price for PATH is projected at USD 15.42 over the next 12 months.
This means that PATH's stock price may go up by +24.69% over the next 12 months.
We can't find any ETFs which contains Uipath Inc's stock.
As per our most recent records Uipath Inc has 4,035 Employees.
Uipath Inc's registered address is One Vanderbilt Avenue, New York, NY, United States, 10017.
You can get more information about it from Uipath Inc's website at https://www.uipath.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Uipath Inc (PATH) Stock
Based on ratings from 15 analysts Uipath Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 30 hold ratings.
Unfortunately we do not have enough data on PATH's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for PATH is USD 15.42 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 12.
PATH stock's Price/Earning ratio is 39.25.
Our analysis grades PATH stock's Price / Earning ratio at D. This means that PATH stock's Price/Earning ratio is above 35% of the stocks in the Software - Infrastructure sector in the NYE exchange.
Based on this PATH may be fairly valued for its sector
The last closing price of PATH's stock was USD 12.37.
The most recent market capitalization for PATH is USD 6.93B.
Based on targets from 15 analysts, the average taret price for PATH is projected at USD 15.42 over the next 12 months.
This means that PATH's stock price may go up by +24.69% over the next 12 months.
We can't find any ETFs which contains Uipath Inc's stock.
As per our most recent records Uipath Inc has 4,035 Employees.
Uipath Inc's registered address is One Vanderbilt Avenue, New York, NY, United States, 10017.
You can get more information about it from Uipath Inc's website at https://www.uipath.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PATH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
